Ireland Sides with Big Pharma in EU Regulatory Debate, Preserving Drug Patent Protections
DUBLIN – Ireland has shifted its stance in a crucial European Union debate, ultimately aligning with major pharmaceutical companies to maintain existing patent protections for new medicines. The decision, which saw Ireland join a coalition of “pro-innovation” countries, effectively blocks proposed EU regulations that would have reduced the period of regulatory data protection for new drugs.
The pharmaceutical industry had lobbied intensely against the proposed changes,arguing that a reduction in patent protection would stifle innovation and economic competitiveness in Europe. In a letter dated March 7th, pfizer informed a senior adviser to EU industry commissioner Stéphane Séjourné of an “urgent need” for Europe to enhance its economic competitiveness considering “recent geopolitical developments.”
Michaela Hagenhofer, head of Johnson & Johnson‘s Irish operations, communicated her opposition to the commission’s plan to cut regulatory protection for new medicines to Irish Minister for Enterprise Peter Burke on February 25th.She requested Ireland’s support in a coalition of countries opposing these changes at the EU level. Similarly, Samantha Humphreys, MSD’s Irish director, urged the government to maintain the “status quo” in a letter dated February 11th. These communications where made public following Freedom of Data Act requests.
However, internal records indicate that the Department of Health favored a “more balanced” approach, suggesting that some changes to the regulations were necessary, according to a March 18th briefing paper. Despite this internal divergence, Taoiseach Leo Varadkar ultimately sided with the industry’s position. Ireland’s revised stance meant joining countries that opposed diluting the “protection” afforded to companies for their newly developed drugs.
The outcome of this debate, settled in an EU vote earlier this year, resulted in national capitals agreeing to keep the eight-year window for regulatory data protection unchanged. A modified version of the new regulations is expected to be finalized in the coming months, marking a important victory for the pharmaceutical sector. This advancement comes as the industry faces the looming “patent cliff,” a period where a significant number of blockbuster drugs lose patent protection, potentially impacting revenues and driving the need for new innovations.
